ASCO meeting 2014


CTC presentations at the American Society for Clinical Oncology

4 June 2014

The CTC and its collaborative investigator groups recently presented their research findings at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago.

  1. Chin VT, Nagrial A, Chantrill LA, Sjoquist KM, O'Connor C, Pajic M, Biankin AV, Yip D. Targeted therapies in the treatment of advanced pancreatic adenocarcinoma: a systematic review and meta-analysis of randomized trials.
  2. Chionh FJM, Gebski V, Cheuh AC, Al-Obaidi SJ, Weickhardt AJ, Lee C, Williams DS, Murone C., Wilson K, Scott AM, Simes J, Price TJ, Mariadason JM, Tebbutt NC. Single nucleotide polymorphisms in vascular endothelial growth factor family genes as predictive or prognostic biomarkers in patients with metastatic colorectal cancer: analysis of the phase III MAX study.
  3. Friedlander M, Stockler MR, Butow PN, Oza AM, O'Connell F, Martyn J, Gillies K, Sjoquist K, King M, ANZGOG and POCOG. Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: the Symptom Benefit study (ANZGOG-0701/ GCIG/PoCoG).
  4. Huguet F, Hammel P, Vernerey D, Goldstein D, Van Laethem JL, Glimelius B, Spry N, S Paget-Bailly, Bonnetain F, Louvet C. Impact of chemoradiotherapy on local control and time without treatment in patients with locally advanced pancreatic cancer included in the international phase III LAP 07 study.
  5. Jonker DJ, Nott LM, Yoshino T, Li C, Gill S, Shapiro JD, Ohtsu A, Zalcberg JR, Vickers MM, Simes J, Wei AC, Mittmann N, Magoski NM, Murray Y, Tsobanis E, Tu D, Kerstein D, O'Callaghan CJ. NCIC CTG and AGITG CO.23 trial: a phase III randomized study of BBI608 plus best supportive care versus placebo plus best supportive care in patients  with pretreated advanced colorectal carcinoma.
  6. Lee C, Davies L, Marschner I, Gebski V, Lord S, Di Leo A, Johnston SRD, Geyer CE, Cameron DA, Press MF, Ellis CE, Loi S, Simes J, De Souza P. Prognostic, predictive, and surrogate value of HER2 extracellular domain for progression-free survival in advanced breast cancer treated with lapatinib: a meta-analysis.
  7. Mileshkin LR, Narayan K, Moore KN, Moore KN, Rischin D, King M, Kolodziej I, Martyn J, Friedlander M, Quinn M, Small W, Thomas G, Fyles AW, Gebski V, Stockler M, ANZGOG GOG and RTOG. A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174).
  8. Nagrial A, Long A, Chin VT, Carter JR, Beale PJ. Duration of systemic therapy for ovarian cancer: a systematic review and meta-analysis.
  9. Price TJ, Bruhn MA, Lee C, Hardingham JE, Townsend AR, Mann K, Simes J, Weickhardt A, Wrin JW, Wilson K, Gebski V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab with or without mitomycin C in advanced colorectal cancer.
  10. Rischin D, Beales PJ, Rossi EC, Goh JC, Vaughan MM, ME Tenney, Martyn J, Sommeijer DW, Iglesias JL, Kremmidiotis G, Simpson JA, Doolin EE
  11. Lavarnos, TC, Leske AF, Veillard AS, Stockler M, ANZGOG and HOG. A phase I study of the vascular-disrupting agent BNC105P in combination with gemcitabine-carboplatin in platinum-sensitive ovarian cancer patients in first or second relapse.
  12. Saad ED, Coart E, Sommeijer DW, Shi Q, Zalcberg JR, Burzykowski T, Meyers JP, Hoff PM, Hecht R, Hurwitz H, Tol J, Tebbutt NC, Fuchs CS, Diaz-Robio E, Souglakos J, Falcone A, Kabbinavar FF, Sargent DJ, De Gramont A, Buyse ME, for the ARCAD Group. Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer: analysis of individual patient data from the ARCAD database.
  13. Schmoll HJ, Haustermans K, Price TJ, Nordlinger B, Hofheinz R, Daisne JF, Janssens J, Brenner B, Schmidt P, Reinel H, Hollerbach S, Caca K, Fauth FWB, Hannig C, Zalcberg JR, Tebbutt NC, Mauer ME, Messina CGM, Lutz MP, Van Cutsem E. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis.
  14. Sjoquist KM, Friedlander M, Mileshkin LR, Quinn M, Goh JC, Shannon CM, Bowtell D, Plebanski M, Yip S, Carlton K, Gillies K, Martyn J, Gebski V, ANZGOG, CTC NHMRC. The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.
  15. Sjoquist KM, Sommeijer DW, Lombard JM, Mileshkin LR, Beale PJ, Grant PT, Blomfeld P, Quinn M, Hadley AM, Sykes P, Antill YC, O'Connell R, Martyn J, Gillies K, Cannan D, Gebski V, Stockler MR, Edmondson RJ, Amant F, Friedlander M, ANZGOG, GCIG, NHMRC CTC. The PARAGON phase 2 trial of anastrozole in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.
  16. Sommeijer DW, Shi Q, Saad ED, Coart E, Buyse ME, Burzykowski T, Meyers JP, Maughan T, Adams RA, Seymour MT, Saltz L, Goldberg RM, Douillard JY, Schmoll HJ, Punt CJA, Tournigand C, Chibaudel B, De Gramont A, Sargent DJ, Zalcberg JR, Group For the ARCAD. Early predictors of prolonged overall survival in patients (pts) on first-line chemotherapy for metastatic colorectal cancer: an ARCAD study with individual patient data on 10,962 patients.
  17. Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Moore M, André T, Mineur L, Chibaudel B, Louvet C, Bonnetain F. Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.
  18. Waring PM, Desai J, Rudzki ZB, Wilson K, Gebski V, Nott LM, Karapetis CS, Khasraw M, Underhill C, Pavlakis N, Chantrill LA, Shapiro J, Segelov E. Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer.